利卡西平

利卡西平
	Top: (R)-(−)-licarbazepine; Bottom: (S)-(+)-licarbazepine
臨床資料
ATC碼	未分配;
藥物動力學數據
血漿蛋白結合率	<40%
代謝產物	Glucuronides
排泄途徑	Mainly renal
識別資訊
	IUPAC命名法 (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide; ;
CAS號	29331-92-8
PubChem CID	114709;
ChemSpider	102704;
UNII	XFX1A5KJ3V;
KEGG	D09215;
ChEMBL	ChEMBL1067;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID50865484 ;
ECHA InfoCard	100.122.427
化學資訊
化學式	C15H14N2O2
摩爾質量	254.29 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
手性	Racemic mixture
	SMILES NC(=O)N1c2ccccc2CC(O)c3ccccc13;
	InChI InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19); Key:BMPDWHIDQYTSHX-UHFFFAOYSA-N;

參考文獻

^ Singh RP, Asconapé JJ. A review of eslicarbazepine acetate for the adjunctive treatment of partial-onset epilepsy. Journal of Central Nervous System Disease. 2011, 3: 179–87. PMC 3663619  . PMID 23861647. doi:10.4137/JCNSD.S4888.
^ Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. June 2012, 53 (6): 935–46. PMID 22612290. S2CID 21233948. doi:10.1111/j.1528-1167.2012.03519.x  .

臨床資料
Top: (R)-(−)-licarbazepine Bottom: (S)-(+)-licarbazepine
ATC碼	未分配
藥物動力學數據
血漿蛋白結合率	<40%
代謝產物	Glucuronides
排泄途徑	Mainly renal
識別資訊
IUPAC命名法 (RS)-10,11-Dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5-carboxamide
CAS號	29331-92-8
PubChem CID	114709
ChemSpider	102704
UNII	XFX1A5KJ3V
KEGG	D09215
ChEMBL	ChEMBL1067
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID50865484
ECHA InfoCard	100.122.427
化學資訊
化學式	C₁₅H₁₄N₂O₂
摩爾質量	254.29 g·mol⁻¹
3D模型（JSmol（英語：JSmol））	交互式圖像
手性	Racemic mixture
SMILES NC(=O)N1c2ccccc2CC(O)c3ccccc13
InChI InChI=1S/C15H14N2O2/c16-15(19)17-12-7-3-1-5-10(12)9-14(18)11-6-2-4-8-13(11)17/h1-8,14,18H,9H2,(H2,16,19) Key:BMPDWHIDQYTSHX-UHFFFAOYSA-N